AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$ROIV

Epperly Melissa B, sold $196K of ROIV

Epperly Melissa B, sold 4,938 shares of Roivant Sciences Ltd. (ROIV) at an average of $39.74 ($39.65–$40.38, $0.20M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epperly Melissa B,
Published Sep 17, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
medium confidence
Mentioned
$ROIV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

The disclosed sale provides a data point for monitoring insider sentiment but is unlikely to drive price movement.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 5/10Timing: filed after market on 2026-09-17

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ROIVBearishMedium confidence
Context

Director Melissa Epperly sold 4,938 shares (~$196K) via a 10b5-1 plan on 2026-09-15.

Expected impact

Minimal short-term price dip, likely within normal volatility range.

Evidence & confidence

The transaction represents less than 0.2% of outstanding shares and is pre‑arranged, limiting informational value.

Market effects

Sector

No material impact on the biotech sector; insider activity is routine.

Regional

Limited to US investors tracking Roivant; negligible broader market effect.

Global

None

Counterpoint

What could challenge this read

The sale could be purely portfolio rebalancing; not a bearish signal.

Key entities

  • Company
    Roivant Sciences Ltd.

    Biopharma company listed on Nasdaq under ticker ROIV.

  • Individual
    Melissa B. Epperly

    Director of Roivant Sciences Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 23
$ROIVHighAI 9/10

Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials

Roivant Sciences shares rose 8% after brepocitinib met primary and secondary endpoints in two Phase 3 trials for non-infectious uveitis. The drug, already approved for dermatomyositis, showed significant improvement over placebo. Roivant plans an FDA filing for the new indication in early 2027. The company has $3.84 billion in cash and a market cap of about $25 billion.

finance.yahoo.com2 min
OCT 21
$ROIVHighAI 9/10

Why is Roivant Sciences stock rallying today?

Roivant Sciences (ROIV) rose 6.8% after its drug brepocitinib met all primary and secondary endpoints in Phase 3 trials for non-infectious uveitis. The company plans to submit an FDA application in 2027. Citi analyst Samantha Semenkow has a $46 price target and Buy rating on ROIV, citing the trial results. The stock reached $37.30, near its 52-week high of $42.50.

investing.com2 min
OCT 21
$ROIVHighAI 9/10

Roivant Sciences stock surges on positive uveitis trial data

Roivant Sciences (NASDAQ:ROIV) shares rose 9% premarket after announcing brepocitinib met all Phase 3 trial endpoints for non-infectious uveitis. The drug showed significant benefit over placebo in both CLARITY-1 and CLARITY-2 trials. Priovant Therapeutics, a Roivant subsidiary, plans to file a supplemental New Drug Application in the first half of 2027.

investing.com2 min